Notice: Undefined index: HTTP_ACCEPT_LANGUAGE in C:\inetpub\wwwroot\technology_detail.php on line 331
 Technology Detail


The Office of Technology Licensing was established in 1970 to transfer technologies developed at Stanford. Find out more about OTL's history, mission, staff, and statistics.

Login to TechFinder » 

εPKC and γPKC Antagonists for Treatment of Withdrawal from Drugs of Abuse


Stanford Reference:

02-104


Abstract


Dr. Mochly-Rosen and colleagues have developed antagonists to εPKC and γPKC that can alleviate the symptoms associated with withdrawal from addictive substances. Withdrawal from addictive drugs such as opiates and alcohol is an unpleasant condition that includes heightened sensitivity to stimuli and an exaggerated pain response. The unpleasantness of withdrawal is a component that reinforces addiction and interferes with successful treatment. There is a continuing need for compounds that can alter desire for addictive drugs by managing the withdrawal symptoms. The εPKC and γPKC antagonists described by this technology can be used to alleviate the symptoms associated with withdrawal.


Applications


  • Treatment of withdrawal symptoms in:
    • Opiate addicts
    • Alcohol addicts
    • Nicotine addicts
    • Infants born to addicted mothers

Advantages


  • Addresses the mechanism of withdrawal hypersensitivity rather than merely sedating the patient
  • Potential to reduce side effects
  • Potential to increase success rate of drug treatment programs

Publications



Marketing




Related Web Links



Innovators & Portfolio



Patent Status



Date Released

 2/3/2014
 

Licensing Contact


Sara Nakashima, Licensing Associate
650 725 9115 (Direct)
Login to Request Information

[-] Map/Timeline

93-168 Peptides That Modulate Interaction Between PKC and RACK
96-103 εPKC Agonists to Provide Cardioprotection
00-252 Isozyme-selective PKC Inhibitors and Activators

more technologies »

Related Keywords


withdrawal treatment   epsilon protein kinase C   pain management   PKC   protein kinase   protein kinase c   protein kinase inhibitors   
 

   

  

Also of Interest...
93-168 Peptides That Modulate Interaction Between PKC and RACK
96-103 εPKC Agonists to Provide Cardioprotection
00-252 Isozyme-selective PKC Inhibitors and Activators

Recently Viewed...
S02-104 εPKC and γPKC Antagonists for Treatment of Withdrawal from Drugs of Abuse